Influenza VaccineNCT04230343
Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza Vaccination Behaviour
A study testing Self-benefit message and Other-benefit message in people with Influenza Vaccine and Behavioral Intervention, run by SB Istanbul Education and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Influenza vaccine uptake remains low worldwide, inflicting substantial costs to public health and health systems. Messages promoting social welfare have been shown to increase vaccination intentions, and it has been recommended that health professionals communicate the socially beneficial aspects of vaccination. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Influenza Vaccine, Behavioral Intervention, Self-benefit
- What is being tested?
- Self-benefit message and Other-benefit message
- Type of treatment
- Vaccines, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 244 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 13 Nov 2016to 25 Mar 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients hospitalized at medical departments of the hospital who are on the day of discharge
Who cannot join
- Egg ellergy
- Previous allergic reaction to influenza vaccine
- Pregnancy
- Cognitive disability
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
SB Istanbul Training and Research Hospital
Istanbul, 34098
About this study
Official title: Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza
Influenza vaccine uptake remains low worldwide, inflicting substantial costs to public health and health systems. Messages promoting social welfare have been shown to increase vaccination intentions, and it has been recommended that health professionals communicate the socially beneficial aspects of vaccination. This study aims to provide the first test whether this prosocial vaccination hypothesis applies to the actual vaccination behaviour of high-risk patients by comparing the effects of two motivational messages for promoting vaccination at a tertiary care public hospital in Istanbul, Turkey.
- Being tested
- Self-benefit message, Other-benefit message
- Medical subject headings
- Influenza, Human
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Self-benefit messageBehavioural
A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine and included a figure of one smiley face.
Other-benefit messageBehavioural
A pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine, and gaining immunity would lower the chances of transmitting the disease to others. The figure included one smiley face surrounded by three other smiley faces.
| Study group | Role | What they receive |
|---|---|---|
| Self-benefit arm | Experimental | Not described Receives: Behavioral: Self-benefit message |
| Social-benefit arm | Active comparator | Not described Receives: Behavioral: Other-benefit message |
What is being measured
The primary outcome is the main question the study is designed to answer.
Vaccine uptake following the introduction of the pamphlet
Difference in the number of patients in each arm who agree to receive influenza vaccine following the introduction of the pamphlet. The first half of the pamphlet contains information about the the influenza vaccine and the risk groups who are vulnerable to influenza-associated serious diseases. The second half introduces the self-benefit message. And the final part asks if the participant wants to receive the influenza vaccine now.
Measured: On the same day, upto 24 hours
Secondary outcomes (1)
Vaccine uptake in high and low risk group patients following the introduction of the pamphlet
Vaccine uptake in high and low risk group patients. The first half of the pamphlet contains information about the the influenza vaccine and the risk groups who are vulnerable to influenza-associated serious diseases. The second half introduces the social-benefit message. And the final part asks if the participant wants to receive the influenza vaccine now.
Measured: On the same day, upto 24 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jan 2020
- Study start13 Nov 2016
- Primary completion25 Mar 2017
- Study completion25 Mar 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Influenza VaccineStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Care provider, Investigator
- Enrolment
- 244 participants (actual)
Sponsor and investigators
- Lead sponsor
- SB Istanbul Education and Research Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University of Nottingham
- Responsible party
- Principal investigator, Burcu Isler, SB Istanbul Education and Research Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04230343
- Sponsor's protocol ID
- 855 - 21/10/2016
- Status last verified
- Jan 2020
- First submitted
- 12 Jan 2020
- Last updated
- 18 Jan 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Isler O, Isler B, Kopsacheilis O, Ferguson E. Limits of the social-benefit motive among high-risk patients: a field experiment on influenza vaccination behaviour. BMC Public Health. 2020 Feb 17;20(1):240. doi: 10.1186/s12889-020-8246-3.
PubMed 32066407
Study at a glance
From the registry record, last updated by the sponsor on 18 Jan 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Limits of the Social Benefit Motive Among High-risk Patients: a Field Experiment on Influenza
- ClinicalTrials.gov ID
- NCT04230343
- Acronym / sponsor ID
- 855 - 21/10/2016
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 244 participants (actual)
- Lead sponsor
- SB Istanbul Education and Research HospitalUniversity, hospital or other
- Collaborators
- University of Nottingham
- Study start
- 13 Nov 2016 (actual)
- Primary completion
- 25 Mar 2017 (actual)
- Study completion
- 25 Mar 2017 (actual)
- First posted
- 18 Jan 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Influenza vaccine uptake remains low worldwide, inflicting substantial costs to public health and health systems. Messages promoting social welfare have been shown to increase vaccination intentions, and it has been recommended that health professionals communicate the socially beneficial aspects of vaccination. This study aims to provide the first test whether this prosocial vaccination hypothesis applies to the actual vaccination behaviour of high-risk patients by comparing the effects of two motivational messages for promoting vaccination at a tertiary care public hospital in Istanbul, Turkey.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Self-benefit arm | Experimental | Behavioral: Self-benefit message |
| Social-benefit arm | Active comparator | Behavioral: Other-benefit message |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients hospitalized at medical departments of the hospital who are on the day of discharge
Key exclusion criteria (4 listed)
- Egg ellergy
- Previous allergic reaction to influenza vaccine
- Pregnancy
- Cognitive disability
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Self-benefit messageA pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine and included a figure of one smiley face. | Behavioural | Self-benefit arm |
| Other-benefit messageA pamphlet consisting of a short text and an abstract figure. The top half of the pamphlet described the official criteria for qualifying to be in the risk group. Bottom half indicated that one can gain immunity against influenza by getting the vaccine, and gaining immunity would lower the chances of transmitting the disease to others. The figure included one smiley face surrounded by three other smiley faces. | Behavioural | Social-benefit arm |
Primary outcome
Vaccine uptake following the introduction of the pamphlet
Time frame: On the same day, upto 24 hours
Difference in the number of patients in each arm who agree to receive influenza vaccine following the introduction of the pamphlet. The first half of the pamphlet contains information about the the influenza vaccine and the risk groups who are vulnerable to influenza-associated serious diseases. The second half introduces the self-benefit message. And the final part asks if the participant wants to receive the influenza vaccine now.
1 secondary outcome
Vaccine uptake in high and low risk group patients following the introduction of the pamphlet
Time frame: On the same day, upto 24 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jan 2020.
- Derived from this study: PubMed 32066407Isler O, Isler B, Kopsacheilis O, Ferguson E. Limits of the social-benefit motive among high-risk patients: a field experiment on influenza vaccination behaviour. BMC Public Health. 2020 Feb 17;20(1):240. doi: 10.1186/s12889-020-8246-3.
- Individual participant dataSharing planned: No
Related trials for Influenza Vaccine
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
RecruitingPhase 2
BPL-1357 Against H1N1 Influenza Virus Challenge
Influenza, Human
Not yet recruitingPhase 1
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
Influenza
RecruitingPhase 1
pH1N1 Blinded Challenge Study
Influenza
RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Influenza
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Self-benefit message and Other-benefit message in people with Influenza Vaccine and Behavioral Intervention, run by SB Istanbul Education and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Vaccine uptake following the introduction of the pamphlet (time frame: On the same day, upto 24 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04230343, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jan 2020.